Varicella zoster antibody titers after the administration of intravenous immune serum globulin or varicella zoster immune globulin.
Varicella is a serious infection in the immunocompromised patient. Prophylaxis with varicella zoster immune globulin is known to decrease the incidence of severe varicella infection. The titers of antibody to varicella zoster virus were compared in patients who received either varicella zoster immune globulin or intravenous immune globulin, 4 ml or 6 ml/kg per dose. The titers of antibody to varicella zoster virus were comparable in each group.
D000293:Adolescent; D000361:Agammaglobulinemia / Q000150:complications; D000914:Antibodies, Viral / Q000096:biosynthesis*; D002648:Child; D002675:Child, Preschool; D004306:Dose-Response Relationship, Immunologic; D006562:Herpes Zoster / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage* / Q000276:immunology; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000276:immunology / Q000378:metabolism; D016756:Immunoglobulins, Intravenous; D007263:Infusions, Parenteral / Q000009:adverse effects
D000914:Antibodies, Viral; D007106:Immune Sera; D007074:Immunoglobulin G; D016756:Immunoglobulins, Intravenous; C030799:varicella-zoster immune globulin